companiesCompany
Linnaeus Therapeutics
aka Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics is a New Jersey biotech whose oral drug LNS8801 activates the oestrogen receptor GPER, a pathway that pushes melanoma cells to stop dividing and become visible to the immune system.
Overview
Linnaeus Therapeutics develops LNS8801, an orally available agonist of the G protein-coupled oestrogen receptor (GPER), based on University of Pennsylvania research showing that GPER activation drives melanoma differentiation and lowers c-Myc. LNS8801 has been tested alone and with pembrolizumab in phase 1/2 trials in cutaneous melanoma and uveal melanoma, including patients who had progressed on checkpoint inhibitors.
Headquarters
Haddonfield, New Jersey, US
Scorecard
All companies#343of 1181 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Type
biotech